Effects of linagliptin monotherapy compared with voglibose on postprandial blood glucose responses in Japanese patients with type 2 diabetes: Linagliptin Study of Effects on Postprandial blood glucose (L-STEP).

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Diabetes Research and Clinical Practice

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.diabres.2016.09.014PMID 27710821
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies

  2016cited by this paper
• China type 2 diabetes treatment status survey of treatment pattern of oral drugs users

  2015cited by this paper
• Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance

  2015cited by this paper
• Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment

  2014cited by this paper
• Early therapy for type 2 diabetes in China.

  2014cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• Long‐term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32)

  2013cited by this paper
• Linagliptin Improves Insulin Sensitivity and Hepatic Steatosis in Diet-Induced Obesity

  2012cited by this paper
• 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.

  2012cited by this paper
• Linagliptin Increases Incretin Levels, Lowers Glucagon, and Improves Glycemic Control in Type 2 Diabetes Mellitus

  2012cited by this paper
• Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

  2012cited by this paper
• Is There a Role for α-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?

  2012cited by this paper
• Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin *

  2011cited by this paper
• Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men

  2011cited by this paper
• The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

  2010cited by this paper
• Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double‐blind trial

  2010cited by this paper
• The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

  2010cited by this paper
• Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.

  2009cited by this paper
• Insulin signaling in alpha cells modulates glucagon secretion in vivo.

  2009cited by this paper
• No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon‐like‐peptide‐1 administration in fasting healthy subjects

  2009cited by this paper
• Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance

  2008cited by this paper
• Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.

  2006cited by this paper
• The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes)

  2005cited by this paper
• Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

  2004cited by this paper
• Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

  2004cited by this paper
• Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases?

  2003cited by this paper
• Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

  2003cited by this paper
• Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

  2003cited by this paper
• Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?

  2003cited by this paper
• Biological actions and therapeutic potential of the glucagon-like peptides.

  2002cited by this paper
• Monotoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas.

  2002cited by this paper
• Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes.

  2002cited by this paper
• Effects of Once-Daily and Twice-Daily Dosing on Adherence With Prescribed Glipizide Oral Therapy for Type 2 Diabetes

  2002cited by this paper
• Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

  1996cited by this paper
• Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

  1993cited by this paper
• Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily

  1988cited by this paper
• Glucagon physiology and pathophysiology in the light of new advances

  1985cited by this paper
• Abnormal Alpha Cell Function in Diabetics Response to Insulin

  1972cited by this paper

• Dipeptidyl Peptidase-4 Inhibitors Improved Lipid Levels in Patients With Type 2 Diabetes: A Meta-analysis of Randomized Clinical Trials.

  2025cites this paper
• Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials

  2022cites this paper
• Efficacy and Safety of Metformin Versus the Other Oral Antidiabetic Drugs in Japanese Type 2 Diabetes Patients: A Network Meta-analysis

  2021cites this paper
• Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose

  2020cites this paper
• Type II diabetes mellitus: a review on recent drug based therapeutics.

  2020cites this paper
• Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials

  2019cites this paper
• Effects of linagliptin versus voglibose on treatment-related quality of life in patients with type 2 diabetes: sub-analysis of the L-STEP study.

  2018cites this paper
• Effects of linagliptin monotherapy compared with voglibose on postprandial lipid profiles in Japanese patients with type 2 diabetes: linagliptin study of effects on postprandial blood glucose (L-STEP) sub-study 1.

  2018cites this paper
• Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes

  2017cites this paper
• Juntendo Medical Journal

  2016cites this paper